+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 75Years
MALE
ID06972511

Apatamide With Maximal Tumor Removal for Oligometastatic Prostate Cancer A Randomized Controlled Trial of Combined Treatment Approaches

Led by RenJi Hospital · Updated on 2025-05-15

120

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Prostate cancer incidence is rising in China, ranking fifth among common male tumors and first in urinary tumors. Unlike in Europe and the United States, prostate-specific antigen screening is less common in China, leading to many patients being diagnosed with metastatic hormone-sensitive prostate cancer mHSPC at an advanced stage. This condition has a low 5-year survival rate of 29.3% and often causes symptoms like bone pain and urinary issues. There is no standard treatment for oligometastatic prostate cancer OMPC, so this trial aims to explore more effective management and treatment strategies to improve patient outcomes and quality of life. The trial compares two treatment approaches an intervention combining neoadjuvant apadamide plus androgen deprivation therapy ADT followed by radical prostate cancer surgery with extended lymph node removal and radiotherapy of metastatic sites, versus standard ADT treatment alone. The neoadjuvant therapy includes apadamide 240 mg daily by mouth and monthly subcutaneous injections of leuproprolirelin for four months before surgery. Radiotherapy is given within three months post-surgery. After treatment, patients receive ongoing ADT until the cancer becomes hormone-resistant, at which point treatment changes. Participants will be monitored regularly for up to five years to assess time to hormone-resistant prostate cancer, overall survival, disease progression, pathological response, PSA levels after six months, quality of life scores, and disease-free survival. The study involves clinical assessments, imaging, and questionnaires to evaluate efficacy and safety. Follow-up continues until disease progression or five years, allowing researchers to gather comprehensive data on the long-term impact of these treatments.

CONDITIONS

Brief Title

Maximal Tumor Eradication for Oligometastatic Prostate Cancer

Research Team

J

JiaHua Pan, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here